Key Points

• Paradigm-shift in disease management with the approval of immuno-oncology agents, namely, checkpoint inhibitors, created a major shift in how patients with cancers are treated.
• The significant clinical impact of checkpoint inhibitors led to what some have seen as a goldrush, others as a bubble, toward clinical development of immunotherapies.
• Immuno-oncology agents have not by and large cured most patients in most cancers, hence new immunotherapeutic agents and combinations are needed.
• Over the past 5 years, much of the BioPharma industry’s focus has been on expanding the range of immuno-oncology agents and combinations.

Complete the information below to download your free copy of the White Paper

For further information about our range of services